DC
Therapeutic Areas
Carmat Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Aeson® Artificial Heart | End-stage biventricular heart failure (Bridge-to-Transplant) | Pivotal Study (U.S.) |
Leadership Team at Carmat
SP
Stéphane Piat
Chief Executive Officer
PM
Pietro M. Ferrari
Chief Commercial Officer
DF
Dr. Francesco Nappi
Chief Medical Officer
PA
Prof. Alain Carpentier
Founder, Chief Scientific Officer, Chairman of Scientific Advisory Board
JC
Jean-Michel Creissel
Chief Financial Officer
BG
Benoît Gausseron
Chairman of the Board of Directors